Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital - Colorado Springs
802
mi
from 91732
Colorado Springs, CO
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital - Colorado Springs
802
mi
from 91732
Colorado Springs, CO
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Lakeland Regional Cancer Center
2161
mi
from 91732
Lakeland, FL
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Lakeland Regional Cancer Center
2161
mi
from 91732
Lakeland, FL
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
1730
mi
from 91732
Chicago, IL
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Rush University
1726
mi
from 91732
Chicago, IL
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Rush University
1726
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
University of Louisville
1812
mi
from 91732
Louisville, KY
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
University of Louisville
1812
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center
2302
mi
from 91732
Baltimore, MD
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medical Institute
2302
mi
from 91732
Baltimore, MD
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medical Institute
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
St. Louis University
1570
mi
from 91732
Saint Louis, MO
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
St. Louis University
1570
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
2515
mi
from 91732
Lebanon, NH
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
2515
mi
from 91732
Lebanon, NH
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Buffalo General Hospital
2180
mi
from 91732
Buffalo, NY
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Buffalo General Hospital
2180
mi
from 91732
Buffalo, NY
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
2181
mi
from 91732
Buffalo, NY
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
2181
mi
from 91732
Buffalo, NY
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Feinstein Institute for Medical Research
2446
mi
from 91732
Great Neck, NY
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Feinstein Institute for Medical Research
2446
mi
from 91732
Great Neck, NY
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
SUNY at Stony Brook Hospital Medical Center
2503
mi
from 91732
Stony Brook, NY
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
SUNY at Stony Brook Hospital Medical Center
2503
mi
from 91732
Stony Brook, NY
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Wake Forest University
2125
mi
from 91732
Winston-Salem, NC
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Wake Forest University
2125
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati
1880
mi
from 91732
Cincinnati, OH
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Ohio State University
1959
mi
from 91732
Columbus, OH
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Ohio State University
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
St. Luke's Hospital
2361
mi
from 91732
Bethlehem, PA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
St. Luke's Hospital
2361
mi
from 91732
Bethlehem, PA
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Geisinger Clinic
2265
mi
from 91732
Danville, PA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Geisinger Clinic
2265
mi
from 91732
Danville, PA
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Pennsylvania State Hershey Cancer Institute
2296
mi
from 91732
Hershey, PA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Pennsylvania State Hershey Cancer Institute
2296
mi
from 91732
Hershey, PA
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
2375
mi
from 91732
Philadelphia, PA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Main Line Surgeons
2369
mi
from 91732
Wynnewood, PA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Main Line Surgeons
2369
mi
from 91732
Wynnewood, PA
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Greenville Hospital System Cancer Center
2019
mi
from 91732
Greenville, SC
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Greenville Hospital System Cancer Center
2019
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Medical Center
1925
mi
from 91732
Knoxville, TN
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Medical Center
1925
mi
from 91732
Knoxville, TN
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
1763
mi
from 91732
Nashville, TN
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Dallas Surgical Group
1221
mi
from 91732
Dallas, TX
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Dallas Surgical Group
1221
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Hunstman Cancer Institute
573
mi
from 91732
Salt Lake City, UT
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Hunstman Cancer Institute
573
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
IHC Cancer Services Intermountain Medical Center
572
mi
from 91732
Salt Lake City, UT
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
IHC Cancer Services Intermountain Medical Center
572
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
University of Virginia
2205
mi
from 91732
Charlottesville, VA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
University of Virginia
2205
mi
from 91732
Charlottesville, VA
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Sentara Careplex Hospital
2323
mi
from 91732
Newport News, VA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Sentara Careplex Hospital
2323
mi
from 91732
Newport News, VA
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
961
mi
from 91732
Seattle, WA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
1654
mi
from 91732
Madison, WI
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center
2134
mi
from 91732
Tampa, FL
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center
2134
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Medical Center
1617
mi
from 91732
Peoria, IL
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Medical Center
1617
mi
from 91732
Peoria, IL
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Newcastle Melanoma Unit
7453
mi
from 91732
Newcastle,
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Newcastle Melanoma Unit
7453
mi
from 91732
Newcastle,
Click here to add this to my saved trials
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
2379
mi
from 91732
Philadelphia, PA
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)
A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
2379
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
A Phase I/II Study of High-Dose Calcitriol in Combination With Temozolomide for Patients With Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
1730
mi
from 91732
Chicago, IL
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
A Phase I/II Study of High-Dose Calcitriol in Combination With Temozolomide for Patients With Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Studies on the Mechanism of Action of High-Dose IL-2 in Metastatic Melanoma and Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Studies on the Mechanism of Action of High-Dose IL-2 in Metastatic Melanoma and Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1463
mi
from 91732
Little Rock, AR
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1463
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
825
mi
from 91732
Aurora, CO
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1793
mi
from 91732
Indianapolis, IN
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1932
mi
from 91732
Ann Arbor, MI
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1357
mi
from 91732
Houston, TX
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1654
mi
from 91732
Madison, WI
A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials